ArticleHematological oncology2025
The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High-Risk Acute Myeloid Leukemia.
Article in Hematological oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Allogeneic hematopoietic stem cell transplantation with liposomal mitoxantrone conditioning for extramedullary leukemia.Investigational new drugs · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite allo-HSCT being the primary curative treatment for high-risk AML, relapse-free survival (RFS) remains suboptimal due to high relapse incidence. Our research focuses on optimizing the conditioning regimen by incorporating Mitoxantrone Hydrochloride Liposome (Lipo-MIT), a novel nano-formulation with enhanced pharmacokinetic properties and demonstrated anti-leukemic efficacy. Preclinical studies have shown that Lipo-MIT significantly improves survival outcomes compared to conventional mitoxantrone, and our study aims to translate these findings into clinical practice. In this study, we present the results of a Lipo-MIT as part of the conditioning regimen for high-risk AML patients undergoing allo-HSCT. Our findings highlight the potential of Lipo-MIT to improve RFS, while also providing insights into patient selection and the refinement of Lipo-MIT-based conditioning strategies. We believe this work contributes valuable knowledge to the field and has the potential to impact clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.